Inhalon Biopharma today announced a new agreement with the University of Georgia to license a panel of Human Metapneumovirus (hMPV) antibodies.
Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that the United States Patent and Trademark Office on October 10, 2023 issued a new U.S. patent to Napo for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with
CureVac N.V. today announced solid progress in its clinical vaccine development programs in COVID-19 and seasonal flu, conducted in collaboration with GSK.
INOVIO today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan.
INOVIO Reports Inducement Grants Under Inducement Plan – November 1, 2023 Read More »
Atara Biotherapeutics Announces Expanded Global Tab-cel ® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results.
The NASH market is expected to evolve because of emerging therapies like MGL-3196, Semaglutide, Vonafexor, HPG1860, VK2809, BIO89-100, LPCN 1144, and others.
SG Austria (“Austrianova”), a leading provider of cell biological products and services, today announced that it has established a German subsidiary company based in Munich and moved to a new location in Singapore.
Austrianova announces German subsidiary and new location in Singapore Read More »
Kyverna Therapeutics (“Kyverna”), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the signing of a multi-year research funding agreement with Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology to investigate the impact of B- and plasma cell-targeting therapies.
Aptatek BioSciences, Inc. has appointed Drawbridge Health Chairperson Lee McCracken as a non-executive director.
Nectero Medical , a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System to treat patients with infrarenal AAA.
